Home / Market News / $SGMT
benzinga Corporate Catalyst Impact 75/100 ● positive

Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE, Including Investigator's Global Assessment Success With A Response Rate Of 57%, 72% Reduction In Total Lesions, And 77% Reduction In Inflammatory Lesions, And Was Generally Well-Tolerated, With No Adverse Event-Related Permanent Discontinuations

Sep 30, 2026, 10:12 AM UTC · Primary ticker $SGMT

Sagimet Biosciences announced positive 52-week results from its Phase 3 OLE clinical trial of denifanstat for moderate to severe acne vulgaris, conducted by its license partner in China. The data showed sustained improvements in efficacy endpoints and good tolerability, reinforcing confidence as Sagimet prepares for its U.S. Phase 3 trial.

Sagimet Biosciences reported positive 52-week results from the Phase 3 OLE trial of denifanstat for acne, conducted by its partner Ascletis in China. This data is crucial as it demonstrates the long-term efficacy and safety of denifanstat, a key drug candidate for Sagimet, and directly supports the upcoming U.S. AURORA Phase 3 clinical trial. The positive results reduce clinical development risk and could lead to increased investor confidence in SGMT, potentially driving short-term stock appreciation. Long-term, successful U.S. trials and eventual approval would open up a significant market opportunity for Sagimet, as denifanstat could be the first oral treatment with a novel mechanism of action for acne in over forty years.

$SGMT positive Positive clinical trial results for key drug candidate
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.